Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Interest & Investment Income (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Interest & Investment Income for 11 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 23.6% year-over-year to $7.1 million, compared with a TTM value of $24.9 million through Dec 2025, up 16.77%, and an annual FY2025 reading of $24.9 million, up 16.77% over the prior year.
  • Interest & Investment Income was $7.1 million for Q4 2025 at Spyre Therapeutics, up from $5.4 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $7.1 million in Q4 2025 and bottomed at $19000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $2.7 million, with a median of $835500.0 recorded in 2023.
  • The sharpest move saw Interest & Investment Income tumbled 92.67% in 2021, then soared 1591.43% in 2024.
  • Year by year, Interest & Investment Income stood at $34000.0 in 2021, then surged by 1105.88% to $410000.0 in 2022, then skyrocketed by 906.34% to $4.1 million in 2023, then soared by 39.99% to $5.8 million in 2024, then increased by 23.6% to $7.1 million in 2025.
  • Business Quant data shows Interest & Investment Income for SYRE at $7.1 million in Q4 2025, $5.4 million in Q3 2025, and $5.9 million in Q2 2025.